BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VGX-3100: Phase I data

Data from an open-label, dose-escalation, U.S. Phase I trial showed that 13 of 18 women with a previous history of cervical intraepithelial neoplasia (CIN) 2/3 treated with 0.6, 2 or 6 mg intramuscular VGX-3100 delivered by Inovio's CELLECTRA electroporation system developed significant antigen-specific cytotoxic T lymphocyte (CTL)...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >